238 related articles for article (PubMed ID: 25179426)
1. How fast up the ladder? Factors associated with immunosuppressive or anti-TNF therapies in IBD patients at early stages: results from a population-based cohort.
Ott C; Takses A; Obermeier F; Schnoy E; Salzberger B; Müller M
Int J Colorectal Dis; 2014 Nov; 29(11):1329-38. PubMed ID: 25179426
[TBL] [Abstract][Full Text] [Related]
2. Crohn's disease and ulcerative colitis. Occurrence, course and prognosis during the first year of disease in a European population-based inception cohort.
Burisch J
Dan Med J; 2014 Jan; 61(1):B4778. PubMed ID: 24393595
[TBL] [Abstract][Full Text] [Related]
3. Cancer in Elderly Onset Inflammatory Bowel Disease: A Population-Based Study.
Cheddani H; Dauchet L; Fumery M; Charpentier C; Marie Bouvier A; Dupas JL; Pariente B; Peyrin-Biroulet L; Savoye G; Gower-Rousseau C
Am J Gastroenterol; 2016 Oct; 111(10):1428-1436. PubMed ID: 27481308
[TBL] [Abstract][Full Text] [Related]
4. Changes in the requirement for early surgery in inflammatory bowel disease in the era of biological agents.
Guasch M; Cañete F; Ordás I; Iglesias-Flores E; Clos A; Gisbert JP; Taxonera C; Vera I; Mínguez M; Guardiola J; Rivero M; Nos P; Gomollón F; Barrio J; de Francisco R; López-Sanromán A; Martín-Arranz MD; Garcia-Planella E; Camargo R; García-López S; de Castro L; Calvet X; Esteve M; Mañosa M; Domènech E;
J Gastroenterol Hepatol; 2020 Dec; 35(12):2080-2087. PubMed ID: 32350906
[TBL] [Abstract][Full Text] [Related]
5. Treatment with immunosuppressive therapy may improve depressive symptoms in patients with inflammatory bowel disease.
Horst S; Chao A; Rosen M; Nohl A; Duley C; Wagnon JH; Beaulieu DB; Taylor W; Gaines L; Schwartz DA
Dig Dis Sci; 2015 Feb; 60(2):465-70. PubMed ID: 25274158
[TBL] [Abstract][Full Text] [Related]
6. Significant differences between Crohn's disease and ulcerative colitis regarding the impact of body mass index and initial disease activity on responsiveness to azathioprine: results from a European multicenter study in 1,176 patients.
Holtmann MH; Krummenauer F; Claas C; Kremeyer K; Lorenz D; Rainer O; Vogel I; Böcker U; Böhm S; Büning C; Duchmann R; Gerken G; Herfarth H; Lügering N; Kruis W; Reinshagen M; Schmidt J; Stallmach A; Stein J; Sturm A; Galle PR; Hommes DW; D'Haens G; Rutgeerts P; Neurath MF
Dig Dis Sci; 2010 Apr; 55(4):1066-78. PubMed ID: 19513841
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic management of inflammatory bowel disease in real-life practice in the current era of anti-TNF agents: analysis of the French administrative health databases 2009-2014.
Kirchgesner J; Lemaitre M; Rudnichi A; Racine A; Zureik M; Carbonnel F; Dray-Spira R
Aliment Pharmacol Ther; 2017 Jan; 45(1):37-49. PubMed ID: 27781286
[TBL] [Abstract][Full Text] [Related]
8. Analysis of Safety, Medical Resource Utilization, and Treatment Costs by Drug Class for Management of Inflammatory Bowel Disease in the United States Based on Insurance Claims Data.
Long GH; Tatro AR; Oh YS; Reddy SR; Ananthakrishnan AN
Adv Ther; 2019 Nov; 36(11):3079-3095. PubMed ID: 31562607
[TBL] [Abstract][Full Text] [Related]
9. Preoperative use of anti-TNF therapy and postoperative complications in inflammatory bowel diseases: a meta-analysis.
Billioud V; Ford AC; Tedesco ED; Colombel JF; Roblin X; Peyrin-Biroulet L
J Crohns Colitis; 2013 Dec; 7(11):853-67. PubMed ID: 23523418
[TBL] [Abstract][Full Text] [Related]
10. Change of treatment modalities over the last 10 years in pediatric patients with inflammatory bowel disease in Switzerland.
Guilcher K; Fournier N; Schoepfer A; Schibli S; Spalinger J; Braegger C; Nydegger A;
Eur J Gastroenterol Hepatol; 2018 Oct; 30(10):1159-1167. PubMed ID: 29985208
[TBL] [Abstract][Full Text] [Related]
11. Steroid dependency and pediatric inflammatory bowel disease in the era of immunomodulators--a population-based study.
Jakobsen C; Munkholm P; Paerregaard A; Wewer V
Inflamm Bowel Dis; 2011 Aug; 17(8):1731-40. PubMed ID: 21744428
[TBL] [Abstract][Full Text] [Related]
12. Generalized Pyoderma Gangrenosum Associated with Ulcerative Colitis: Successful Treatment with Infliximab and Azathioprine.
Chatzinasiou F; Polymeros D; Panagiotou M; Theodoropoulos K; Rigopoulos D
Acta Dermatovenerol Croat; 2016 Apr; 24(1):83-5. PubMed ID: 27149138
[TBL] [Abstract][Full Text] [Related]
13. Long-term prognosis of ulcerative colitis and its temporal changes between 1986 and 2015 in a population-based cohort in the Songpa-Kangdong district of Seoul, Korea.
Cha JM; Park SH; Rhee KH; Hong SN; Kim YH; Seo SI; Kim KH; Jeong SK; Lee JH; Park SY; Park H; Kim JS; Im JP; Yoon H; Kim SH; Jang J; Kim JH; Suh SO; Kim YK; Ye BD; Yang SK
Gut; 2020 Aug; 69(8):1432-1440. PubMed ID: 31822581
[TBL] [Abstract][Full Text] [Related]
14. Systematic review with meta-analysis: comparative efficacy of immunosuppressants and biologics for reducing hospitalisation and surgery in Crohn's disease and ulcerative colitis.
Mao EJ; Hazlewood GS; Kaplan GG; Peyrin-Biroulet L; Ananthakrishnan AN
Aliment Pharmacol Ther; 2017 Jan; 45(1):3-13. PubMed ID: 27862107
[TBL] [Abstract][Full Text] [Related]
15. Natural history of elderly-onset inflammatory bowel disease: a population-based cohort study.
Charpentier C; Salleron J; Savoye G; Fumery M; Merle V; Laberenne JE; Vasseur F; Dupas JL; Cortot A; Dauchet L; Peyrin-Biroulet L; Lerebours E; Colombel JF; Gower-Rousseau C
Gut; 2014 Mar; 63(3):423-32. PubMed ID: 23408350
[TBL] [Abstract][Full Text] [Related]
16. A risk score system to timely manage treatment in Crohn's disease: a cohort study.
Pallotta N; Vincoli G; Pezzotti P; Giovannone M; Gigliozzi A; Badiali D; Vernia P; Corazziari ES
BMC Gastroenterol; 2018 Nov; 18(1):164. PubMed ID: 30400823
[TBL] [Abstract][Full Text] [Related]
17. Upfront Combination Therapy, Compared With Monotherapy, for Patients Not Previously Treated With a Biologic Agent Associates With Reduced Risk of Inflammatory Bowel Disease-related Complications in a Population-based Cohort Study.
Targownik LE; Benchimol EI; Bernstein CN; Singh H; Lix L; Tennakoon A; Leung S; Aviña A; Coward S; Jones J; Kaplan G; Murthy SK; Nguyen GC; Peña-Sánchez JN
Clin Gastroenterol Hepatol; 2019 Aug; 17(9):1788-1798.e2. PubMed ID: 30448599
[TBL] [Abstract][Full Text] [Related]
18. Solid Organ Transplantation in Patients with Inflammatory Bowel Diseases (IBD): Analysis of Transplantation Outcome and IBD Activity in a Large Single Center Cohort.
Schnitzler F; Friedrich M; Stallhofer J; Schönermarck U; Fischereder M; Habicht A; Karbalai N; Wolf C; Angelberger M; Olszak T; Beigel F; Tillack C; Göke B; Zachoval R; Denk G; Guba M; Rust C; Grüner N; Brand S
PLoS One; 2015; 10(8):e0135807. PubMed ID: 26288187
[TBL] [Abstract][Full Text] [Related]
19. Rate of Adverse Events and Associated Health Care Costs for the Management of Inflammatory Bowel Disease in Germany.
Wilke T; Groth A; Long GH; Tatro AR; Sun D
Clin Ther; 2020 Jan; 42(1):130-143.e3. PubMed ID: 31883702
[TBL] [Abstract][Full Text] [Related]
20. Indicators of suboptimal tumor necrosis factor antagonist therapy in inflammatory bowel disease.
Lindsay JO; Armuzzi A; Gisbert JP; Bokemeyer B; Peyrin-Biroulet L; Nguyen GC; Smyth M; Patel H
Dig Liver Dis; 2017 Oct; 49(10):1086-1091. PubMed ID: 28826571
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
